Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Tax Provisions (2021 - 2025)

Arrowhead Pharmaceuticals' Tax Provisions history spans 5 years, with the latest figure at $29000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 71.84% year-over-year to $29000.0; the TTM value through Dec 2025 reached $21.3 million, up 3188.91%, while the annual FY2025 figure was $21.4 million, 874.09% up from the prior year.
  • Tax Provisions reached $29000.0 in Q4 2025 per ARWR's latest filing, down from $20.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $20.0 million in Q3 2025 to a low of -$3.3 million in Q4 2023.
  • Average Tax Provisions over 5 years is $2.3 million, with a median of $546000.0 recorded in 2024.
  • Peak YoY movement for Tax Provisions: surged 189150.0% in 2022, then tumbled 73.04% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $2000.0 in 2021, then soared by 189150.0% to $3.8 million in 2022, then tumbled by 187.53% to -$3.3 million in 2023, then skyrocketed by 103.11% to $103000.0 in 2024, then crashed by 71.84% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Tax Provisions are $29000.0 (Q4 2025), $20.0 million (Q3 2025), and -$437000.0 (Q2 2025).